|
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
|
04 June 2018 |
|
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
|
28 May 2018 |
|
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
|
21 May 2018 |
|
Alcon Cares Project 100 commits to reducing cataract blindness globally
|
10 May 2018 |
|
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
|
01 May 2018 |
|
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
|
25 April 2018 |
|
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
|
17 April 2018 |
|
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
|
09 April 2018 |
|
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
|
23 March 2018 |
|
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
|
20 March 2018 |